As a member of the aldo-keto reductase (AKR) superfamily (www.med.upenn.edu/akr) [1] , AKR family 1 member C3 (AKR1C3) was originally cloned from human liver and prostate cDNA libraries [2, 3] and named type 2 3αhydroxysteroid dehydrogenase (3α-HSD)/type 5 17β-HSD. AKR1C3 is a monomeric cytoplasmic protein with 323 amino acids, a molecular weight of 37 kDa [4, 5] , and shares high sequence homology with related human AKR1C1 (20α-HSDs), AKR1C2 (type 3 3α-HSD) and AKR1C4 (type 1 3α-HSD) [6] . Recombinant AKR1C3 reduces aldehydes and/or ketones to their corresponding alcohols through oxidation of NADH or NADPH to NAD + and NADP + [3] . AKR1C3 was originally shown to have the capability to inactivate the most potent androgen, 5α -dihydrotestosterone (5α-DHT), to form weak androgens, 5α-androstane-3α,17β-diol (3αd i o l ) , 5 α -a n d r o s t a n -3 α -o l -1 7 -o n e (androsterone), and 5α-androstan-3,17-dione (androstanedione) and may regulate ligand Int J Clin Exp Pathol 2012;5(4):278-289 www.ijcep.com /ISSN: 1936-2625/IJCEP1203013
availability for the androgen receptor (AR).
In addition to androgen metabolism, AKR1C3 was shown to be an enzyme possessing 3α-HSD, 3β-HSD, 17β -HSD, and 11ketoprostaglandin reductase activities [3, 4, 6, 7] . These enzymatic properties allow AKR1C3 to metabolize estrogen, progesterone, and prostaglandins (PGs), and may indirectly govern the amount of ligands available to various nuclear receptors, including estrogen receptor (ER), progesterone receptor (PR), and nuclear orphan receptors such as the peroxisome proliferatoractivated receptor (PPAR) [8, 9] . As a result, AKR1C3 can be an intracellular modulator in regulating trans-activation activities of these nuclear receptors in target organs [10] .
Tissue distribution of AKR1C3 has been demonstrated in sex hormone-dependent organs including breast [4] , endometrium [11, 12] , prostate [4, 5] , and testis [13] . De-regulated expression of AKR1C3 has been established in multiple types of hormone-related cancers, including breast cancer [14] , endometrial cancer [11, 12, 15] , and prostate cancer [5, [16] [17] [18] . In addition, AKR1C3 expression has been studied in sex hormone-independent tissues including urothelial epithelium [5] and epithelium of renal tubules [19] . Abnormal AKR1C3 expression has been observed in hormone-independent cancers, including urothelial carcinoma, renal cell carcinoma [5] , brain tumor [20] , and Wilms' tumor [21] . Roles of AKR1C3 in the development and progression of these hormonedependent and independent cancers remain unclear.
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental pollutants including tobacco carcinogens implicated in the causation of human lung cancer. PAHs need to be metabolically activated to exert their carcinogenic effects. Dihydrodiol dehydrogenases (DDs), members of the AKR superfamily, represents a major pathway responsible for PAH activation [22] , and divert PAH trans-dihydrodiols to corresponding o-quinones [23] . Homogenous recombinant AKR1C3 can oxidize a wide variety of PAH transdihydrodiols and yield of o-quinones [22] . While expression of AKR1C isozymes (DDs) in nonsmall cell lung carcinoma and cell lines have been described [24, 25] , AKR1C3-specific expression in lung cancer has not been reported.
In this investigation, we studied spatial distribu-tions of AKR1C3 in normal lung and gastroesophageal junction as well as in small cell and non-small cell carcinoma residing in these locations. A total of 15 cases of small cell carcinoma, 14 cases of adenocarcinoma, and 18 cases of squamous cell carcinoma of the lung were studied. The expression of AKR1C3 in 15 cases of adenocarcinoma and 15 cases of squamous cell carcinoma of the gastroesophageal junction were also studied for comparison.
Materials and methods

Human normal and neoplastic tissue
A total of 77 separate cases of archival, formalin fixed, paraffin embedded biopsy or resection specimens were retrieved. All specimens were obtained through the Department of Pathology at the University of Oklahoma Health Sciences Center with Institutional Review Board (IRB) approval. Cases were limited to those with indisputable diagnostic features, containing sufficient amount of tissues, and free of excessive artifacts. All tumors were primary tumors and all except one were untreated tumors. Normal tissue sections were obtained from histological normal areas within these cases. This consortium included 15 small cell carcinomas, 14 adenocarcinomas, and 18 squamous cell carcinomas of the lung, as well as 15 of adenocarcinomas and squamous cell carcinomas respectively arising from the gastroesophageal junction ( Table 1 ). The diagnosis was reconfirmed by a pathologist in this study (KMF).
Antibody and immunohistochemistry
Monospecific mouse anti-AKR1C3 monoclonal antibody was produced and characterized in our laboratory as described [4] . Paraffin sections were cut at 5 μm thick, deparaffinized and rehydrated. Immunohistochemistry was performed by an automated staining machine (Benchmark, Ventana, Tucson, AZ) with a CC1-medium antigen retrieval protocol described by the manufacture. Primary antibody was applied at 1:200 dilution and incubated for 90 min. Diaminobenzidine and hematoxylin were used as chromogen and counter stain, respectively.
Immunohistochemical evaluation and scoring
The stained tissue sections were evaluated with a conventional light microscope independently by two of the investigators (VLM, KMF). The per- centage of positive cells within the entire tumors were evaluated and allocated to one of the following categories: completely negative, ≤ 5% positive immunoreactivity, > 5% but ≤ 25% positive immunoreactivity, > 25% but ≤ 75% positive immunoreactivity, > 75% but ≤ 100% positive immunoreactivity, and 100% positive immunoreactivity. The intensity of staining was also scored as weak, moderate, or strong for every case. In cases with more than one level of intensity, the staining intensity with the largest area was considered the final score.
Results
Normal lung
Bronchial epithelium ( Figure 1A and 1B) including the cilia were immunoreactive for AKR1C3. Endothelial cells were immunoreactive but the supporting stroma was largely negative. Most of the seromucinous glands within the supporting mucosa were negative. Weak positive immunoreactivity was demonstrated in the cytoplasm and nuclei of scant glandular epithelial cells ( Figure 1A and 1C ). In the alveoli, type II pneumocytes were non-reactive but cytoplasmic immuoreactivity was noted in the alveolar macrophages ( Figure 1D and 1E ). Similar to our prior observations, the immunoreactivity was mainly cytoplasmic but some nuclear immunoreactivities were also noted.
Normal gastroesophageal junction
The superficial layers of the squamous epithelium were negative, whereas the deeper layers of squamous epithelium had patchy positive immunoreactivity ( Figure 1F ). In general, the esophageal glands were negative but weak positive immunoreactivitiy was noted in occasional glandular epithelial cells with atrophic changes ( Figure 1F and 1G). Contents in the lumen of the glands were positive in some of the glands. Strong AKR1C3 immunoreactivity was detected in the gastric type epithelium at the gastroesophageal junction. The superficially located epithelium tended to be stronger in immunoreactivity than those located in the deeper parts of the glands (Figure 1H and 1I ). In the deeper part of the gastric glands, occasional negative glandular epithelial cells among strongly positive epithelial cells were identified ( Figure 1I ).
Squamous cell carcinoma of lung
Of the 18 cases of squamous cell carcinoma of the lung, 12 (66.6%) showed 100% AKR1C3 positive immunoreactivity and, all except one, demonstrated strong immunoreactivity ( Figure  2A ). Another 3 cases (16.6%) showed substantial amounts of immunoreactivity (> 25%) and at least medium intensity ( Figure 2B) ; and the remaining 3 tumors (16.6%), 1 case exhibited either small amount of positive immunoreactivity (< 5%), 1 case expressed weak immunoreactivity ( Figure 2C ), and 1 case is completely negative. Detailed AKR1C3 immunoreactivity is described in Table 1 .
Adenocarcinoma of lung
Of the 14 cases of adenocarcinoma of the lung, strong and 100% immunoreactivity was demon-strated in 4 cases (28.6%) ( Figure 2D ). Focal immunoreactivity (positivity > 5% but ≤ 25%) medium to strong positive immunoreactivity was demonstrated in 7 cases (50%) ( Figure 2E ). The remaining 3 cases exhibited various degrees of AKR1C3 immunoreactivity: 1 case with > 5% but ≤ 25% weak positivity, 1 case with 5% or less positivity but the immunoreactivity was strong ( Figure 2F ), and 1 case was completely negative (Table 1) .
Small cell carcinoma of lung
All 15 cases of small cell carcinoma were completely negative in AKR1C3 immunoreactivity (Table 1 ). However, positive immunoreactivity was detected in the entrapped blood vessels ( Figure 2G ) and residual respiratory type mucosa ( Figure 2G , 2H, and 2I).
Squamous cell carcinoma of gastroesophageal junction
Among the 15 cases of squamous cell carcinoma arising in the gastroesophageal junction (Table 1) , 4 cases (26.7%) showed 100% medium to strong immunoreactivity ( Figure 2J ). Substantial amount of positive immunoreactivity (> 25%) and medium intensity were observed in 6 cases (40%) ( Figure 2K ). One case (6.7%) had small amount (< 5%) but strong immunoreactivity; and another case (6.7%) had small amount (< 5%) of weak immunoreactivity ( Figure 2L ). The remaining 3 cases (20%) were completely negative.
Adenocarcinoma of gastroesophageal junction
In the 15 cases of adenocarcinoma of the gastroesophageal junction, 9 of the cases (60%) showed 100% strong to medium positive immunoreactivity ( Figure 2M ). Another 5 cases (33.3%) demonstrated substantial positive immunoreactivity (> 25%) with medium to strong intensity ( Figure 2N ). One of these cases (6.7%) showed at least 25% positivity but weak immunoreactivity ( Figure 2O ). There was no completely negative case (Table 1 ).
Discussion
As per our immunohistochemical investigation on spatial and cancer-specific distributions of AKR1C3, we demonstrated positive immunoreactivity on bronchial epithelium but not bron- Differentiation of small cell carcinoma from NSCLC carries significant clinical implications because of the differences in treatment and prognosis. The bulk of NSCLC is composed of squamous cell carcinoma and adenocarcinoma. As most carcinomas of the lung are diagnosed by small biopsies, histologic diagnosis could be challenging in some cases. Immunohistochemical confirmation is a common practice in these challenging cases. Currently, a panel of molecular markers is used and this differentiation includes molecules specific for neuroendocrine phenotypes such as synaptophysin and chromogranin [26] , squamous cell differentiation such as p63 protein [26] and cytokeratin 5/6 [26] , and adenocarcinoma such as thyroid transcription-1 and Napsin A [27] . In addition, mucicarmine stain can be helpful in identifying adenocarcinoma by demonstrating mucin in adenocarcinomas that produce mucin. AKR1C3 can be used in conjunction with the existing markers in differentiating small cell carcinoma from NSCLC.
Tobacco smoke and air pollutants contain many kinds of PAHs including benz[a]anthracene (BA) and benzo[a]pyrene (BaP). These compounds require activation to electrophilic metabolites to exert their carcinogenic or mutagenic effects. AKR1C3 may play an important role in BA and BaP carcinogenesis via oxidative DNA damage by catalyzing NAD(P)+-linked oxidation of dihydrodiols of aromatic hydrocarbons to corresponding catechols [28] . The DNA damage caused through the production of reactive metabolites of PAH involve DNA covalent binding to form stable or depurinating adducts, formation of apurinic sites, and oxidative damage [29] . Levels of AKR1C isoenzyme expression are negatively correlated with the formation of BaP DNA adducts in lung cancer cell lines [30] , but positively correlated with oxidative stress [31] . Based on the AKR1C3-mediated PAH metabolism, elevated expression of AKR1C3 in NSCLC suggests that AKR1C3-mediated pathway may contribute to PAH activation in NSCLC. Although elevated AKR1C isoforms expression has been positively correlated with higher incidence of early tumor recurrence, distant metastasis, and poor prognosis of patients with advanced NSCLC [24] , pathological roles of AKR1C3mediated PAH activation in NSCLC development and progression require further study.
One study suggests that AKR1C3 modulates risks for lung cancer due to exposure to PAH; and subjects with AKR1C3-Gln/Gln genotype have a higher risk of lung cancer [32] . A high level of AKR1C isozymes expression has also been shown in A549 cells, a human lung adenocarcinoma cell line [33] . Thus, a mechanism of AKR1C-mediated carcinogenesis in the lung has been proposed. PAH and reactive oxygen species (ROS) induce the expression of AKR1C isozymes. While AKR1C isozymes provides a defense mechanism against the harmful effects of ROS, the increased level of AKR1C isozymes can divert PAH trans-dihydrodiols from P450 peroxidases or CYP superfamily proteins to the deleterious o-quinones which would cause cova- Our results of widespread AKR1C3 expression in NSCLC are consistent with the observation of DDs overexpression in NSCLC by Hsu et al. [24] . In their study, elevated expression of AKR1C transcripts was detected in primary NSCLC by mRNA differential display and confirmed by in situ hybridization using a fluorescence-labeled AKR1C antisense probe; but expression of these mRNA species in normal bronchial epithelium was not described. In a separate study, the expression of DDs was found to be higher in squamous cell carcinoma as determined by immunohistochemical staining using a mouse polyclonal antibody raised against recombinant AKR1C1 [25] . Due to a high nucleotide sequence identity and high amino acids similarities among AKR1C isoforms, in situ hybridization or polyclonal antibody against AKR1C1 cannot be sufficient to identify isoform-specific tissue distribution, but identify all AKR1C isoforms. The monoclonal antibody used in the study has AKR1C3 monospecificity, and does not crossreact with other identified AKR1C isoforms [4] .
In addition to PAH metabolism, AKR1C iszymes could be involved in drug detoxification. The expression levels of AKR1C transcripts are positively correlated with the cells' resistance to cisplatin, adriamycin and radiotherapy in multiple human lung adenocarcinoma cell lines [34] , and resistance to daunorubicin in the human stomach carcinoma cell line EPG85-257 [35] . It has also been demonstrated that elevated AKR1C isozymes expression leads to the induction of resistance to platinum-based drugs in human ovarian, lung, cervical, and germ cell tumor cell lines [36, 37] ; and forced expression of AKR1C3 in human ovarian cells confers a cisplatin resistant phenotype with concomitant generation of ROS [38] . In contrast to keratinocytes, fibroblast, and basal cell carcinoma cell lines that have undetectable or low levels of AKR1C, the human epidermoid carcinoma A431 cells constitutively express high levels of AKR1C isozymes. Targeted suppression of AKR1C expression in A431 cells using small interfering RNA technique significantly increased sensitivity to UVB-induced apoptosis and cytotoxicity of chemotherapeutic agent bleomycin [39] . Elevated expression of AKR1C is also identified in ethacrynic acid-induced drug-resistant human colon cancer HT29 cells using mRNA differential display [40] . The impact of AKR1C3 on drug resistance of lung cancer cells, however, remains to be clarified as to whether this is a mechanism of drug inactivation and detoxification.
Epidemiological studies indicate that there is a gender difference in the susceptibility to tobacco and environmental carcinogens. This gender difference is suspected to result in a higher risk for lung cancer incidence among women. However, molecular mechanisms underlying this sexual dimorphism remain unclear. Estrogen metabolism may contribute to lung cancer in non-smoking women. The ERβ regulates lung development, in particular, alveolar formation and surfactant homeostasis, and has been shown to correlate with the expression of Phase I/II carcinogen-metabolizing enzymes [41, 42] .
In lung tumors, overexpression of ERβ has been observed, and this difference is significantly more common in tumors from nonsmokers (53.5%) than in smokers (36.6%). Among nonsmokers, higher ERβ expression was reported significantly more frequently in female patients (58.3%) than in male patients [43] . In addition, levels of PR transcripts were found to be significantly less in cancerous as compared to nonmalignant lung tissue. Using immunohistochemistry, expression of PR was observed in the nucleus and extra nuclear compartments in the majority of human tumor specimens examined. Combinations of estrogen and progestin administration promote secretion of vascular endothelial growth factor (VEGF) by tumor cells and support tumor-associated angiogenesis in vitro [44] . Furthermore, simultaneous administration of estradiol and progestin increased the numbers of putative tumor stem/progenitor cells. Thus, ER-and/or PR-targeted therapies have been proposed as new approaches to manage NSCLC. It has also been reported that there is an increased incidence of lung cancer associated with increasing duration of estrogen plus progestin use, but no association with duration of unopposed estrogen use [45] . AKR1C3 is involved in estrogen and progesterone metabolism and is capable of regulating the occupancy of the ER and PR. The study of AKR1C3regulated estrogen and progesterone levels, as well as ER and PR trans-activation in the development and progression of lung cancer may delineate important pathways involved in hormone metabolism and lung cancer.
In conclusion, AKR1C3 immunoreactivity was specifically detected in squamous cell carcinoma and adenocarcinoma of the lung and gastroesophageal junction but not in small cell carcinoma of the lung. Thus, AKR1C3 and other AKR1C isozymes might be used as adjunct markers to differentiate small cell carcinoma from adenocarcinoma and squamous cell carcinoma which constitute the bulk of NSCLC. AKR1C3 has multiple substrates including steroids, PG, PAH, and cancer chemotherapeutic drugs. Preliminary evidence proposes that AKR1C3 may contribute to the defense of ROS in carcinogenesis but its significance in carcinogenesis remain unclear. The widespread expression of AKR1C3 in columnar epithelium of both the bronchial epithelium and the gastrointestinal junction suggest that it may not only play a role as a chemical barrier to xenobiotics but may also be involved in lung carcinogen metabolism. These biological and pathological properties of the multifunctional enzyme are worthwhile for future investigations.
